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The secret of The Secret History of the War on
Cancer is prevention, an acutely recognized
but long neglected solution to workplace-,
environmental-, and public health–
associated cancers. Davis begins by asking
what we know and how much we need to
know about suspected carcinogens before
taking the actions necessary to reduce or
eliminate exposures to known and sus-
pected carcinogens. Hence prevention. 
This assured strategy of preventing can-
cer versus treating cancer has been virtually ignored
by national health and regulatory agencies, writes Davis,
whereupon she describes the interconnections of industry, science,
and government to maintain the status quo. Few of the hundreds of known
carcinogens have been banned from use. Occupational exposure standards
have been established for only a relatively small number of chemical carcino-
gens, and even here the chemical industry wields considerable and influential
political power. Pioneering public health–minded individuals such as
Lorenzo Tomatis and David Rall made great strides in primary prevention of
diseases from chemicals, but their efforts were met with overwhelming resis-
tance by government and industry to their relatively simple strategies for
reducing cancer burdens. Davis presents in detail primary prevention tactics
that could be easily implemented. 
For example, Davis chronicles prevention efforts from the Surgeon
General’s 1965 declaration that smoking causes cancer to the present, as well
as feeble efforts to thwart tobacco smoking. She writes that the strength of
the tobacco industry and the malfeasance of politicians and regulatory agen-
cies combined to prevent public health action, thus condoning nearly
500,000 preventable deaths each year. She describes similar failures to pre-
vent exposure to asbestos, lead, and industrial chemicals.
Davis details with striking historical perspective how those with interests
in maintaining the use of carcinogens in industry cast doubt on epidemiologic
research. Industry considers only epidemiologic evidence as potential proof of
harm, even though the evidence is always vociferously challenged; conversely,
industry promotes “the absence of human studies [as] proof that there was no
harm.” But animal studies are rarely considered by industry or regulatory agen-
cies as sufficient evidence to prove harm, because in their view the similarities
and extrapolation to humans are not valid. As amply illustrated by Davis, these
debates have intensified over time, as have the attempts to control scientific
information: “What information is permitted to get to the marketplace, who
decides when to release findings about public health hazards, all these things
are not determined by scientific inquiry but by the social and economic reali-
ties that constrain them.” For example, in the mid-1970s when the
Occupational Safety and Health Administration (OSHA) used incontrovert-
ible human evidence of benzene-induced leukemias to reduce workplace
exposures to benzene, a known carcinogen since the late 1920s, industry was
able to thwart these reductions because the U.S. Supreme Court ruled that
OSHA did not consider the benefits versus risks in their evaluation. Ten
more years went by before the standards were strengthened. 
Clearly, Davis writes, profit is the key issue. Reducing exposures report-
edly costs the affected industries more money than they can afford or want to
spend and still make profits. For example, workers cleaning vinyl chloride (VC)
reaction vats developed the same rare form of liver cancer (hemangiosarcoma)
as first seen in animals, and the plastics industry was ordered to reduce/
eliminate exposures to VC—but was not required to initiate any changes until
there was verifiable evidence of cancer in humans. Instead, industry stated that
the risks were “small” and that the plastics industry would not survive. Losing
this argument and using their ingenuity rather than further litigation, industry
automated the process and eliminated the need to manually clean VC reaction
vats, actually making the process more streamlined and safe as well as more
cost-effective and concomitantly reducing the workers’ risks of cancer. 
The real debates and struggles arise when animal data show unequivocal
carcinogenicity, but with no studies available in humans. Davis notes the con-
siderable evidence that animal cancer data do indeed predict carcinogenic
risks to humans. Scientists such as Davis and regulators who believe in the
value of bioassays for public health cite at least five reasons supporting the
continuation of bioassays and using this information to protect the public
from unnecessary exposures to carcinogens: there are more similarities among
mammals (humans and rodents) than differences; all accepted human car-
cinogens are also carcinogenic in animals; there are common cancer sites
between animals and humans; nearly one-third of the identified human car-
cinogens were discovered first in animal bioassays; and findings from inde-
pendently conducted adequate bioassays on the same chemicals are consistent.
The Secret History of the War On Cancer, exhaustively researched and
deftly written, illuminates more of the truth about chemicals and cancer and
the relatively simple means of preventing or reducing cancer burdens. Davis
emphasizes that “It’s time to admit that our efforts have often targeted the
wrong enemies and used the wrong weapons.” This exposé should be required
reading in toxicology courses and also be made available in high school, col-
lege, public health libraries, and libraries in general. The message is clear: To
reduce cancers, one need only reduce unnecessary exposures to mutagens and
carcinogens as well as to chemicals in general. 
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